EUVIMEDEUVIMED entdecken
Crossref

Additive and Antagonistic Effects among Combination of Agonists of Peroxisome Proliferator-Activated Receptor gamma (PPARg) on Transcriptional Activity

Daisuke Tsuriya, Hiroshi Morita, Tetsu Morioka, Shigekazu Sasaki, Yutaka Oki, Hirotoshi Nakamura

Diabetes Research - Open Journal · 2015

DOI: 10.17140/droj-1-105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Research - Open Journal, 2015. Verfasst von Daisuke Tsuriya und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The Angiotensin-II receptor blocker telmisartan and sulfonylurea glimepiride may have clinical usefulness as partial agonists of PPARg.We investigated additive and antagonistic effects among combinations of telmisartan, glimepiride, and the Thiazolidinedione (TZD) selective PPARg agonist pioglitazone on transcriptional activity of PPARg. Materials/Methods:The receptors of pCMX-PPARg and pCMX-RXR, and PPRE-Luc reporter gene were transfected into CV1 cells, and treated with following agents, and luciferace assay was performed.Moreover, mammalian two-hybrid assay was done using GAL4 responsive reporter tk-MH100(UAS)×4-Luc and the chimeric receptor GAL4-PPARg.

Results

Telmisartan increased transactivation of PPARg dose dependently.Activation by telmisartan 10 µM was 58.8% of that by pioglitazone 10 µM.Glimepiride also increased transactivation of PPARg dose dependently.Activation by glimepiride 10 µM was 49.8% of that by pioglitazone 10 µM.Addition of telmisartan 5 µM significantly enhanced transactivation by glimepiride 10 and 50 µM.Moreover, addition of pioglitazone 0.5 µM significantly enhanced transactivation by glimepiride 10 and 50 µM.Mammalian two-hybrid assay showed additive effect between glimepiride and telmisartan on binding of SRC-1 to PPARg.On the other hand, addition of glimepiride 10 and 50 µM reduced transactivation by pioglitazone 5 µM to 74% and 70%, respectively.

Conclusion

Partial agonists of PPARg additively enhanced transactivation by other agonists, whereas high concentration of partial agonists reduced transactivation by full agonist antagonistically.

Zitieren

APA

Tsuriya, D., Morita, H., Morioka, T., Sasaki, S., Oki, Y., & Nakamura, H. (2015). Additive and Antagonistic Effects among Combination of Agonists of Peroxisome Proliferator-Activated Receptor gamma (PPARg) on Transcriptional Activity. Diabetes Research - Open Journal. https://doi.org/10.17140/droj-1-105

Vancouver

Tsuriya D, Morita H, Morioka T, Sasaki S, Oki Y, Nakamura H. Additive and Antagonistic Effects among Combination of Agonists of Peroxisome Proliferator-Activated Receptor gamma (PPARg) on Transcriptional Activity. Diabetes Research - Open Journal. 2015. doi:10.17140/droj-1-105

BibTeX
@article{Tsuriya2015,
  author = {Tsuriya, Daisuke and Morita, Hiroshi and Morioka, Tetsu and Sasaki, Shigekazu and Oki, Yutaka and Nakamura, Hirotoshi},
  title = {Additive and Antagonistic Effects among Combination of Agonists of Peroxisome Proliferator-Activated Receptor gamma (PPARg) on Transcriptional Activity},
  journal = {Diabetes Research - Open Journal},
  year = {2015},
  doi = {10.17140/droj-1-105}
}
Kostenlos starten →